Earlier invasive fungal infections (IFI) put recipients of hematopoietic SCT (HSCT) at a high risk of IFI-related mortality. We retrospectively assessed the feasibility of HSCT for patients with a history of IFI and the efficacy of secondary prophylaxis. From January 2001 to December 2007, 49 patients with a history of IFI underwent HSCT and most of them received broadspectrum antifungal agents as secondary prophylaxis. After a median follow-up of 355 days (15-967), nine patients experienced failure of IFI prophylaxis, including three cases of IFI-related death, leading to a 2-year cumulative incidence of 18.4 and 6.1%, respectively. Four risk factors for the failure of prophylaxis were found, namely time interval from the diagnosis of IFI to transplantation, residual diseases before transplantation, infection with CMV and use of corticosteroid for the treatment of GVHD. A similar outcome can be achieved in recipients of Auto-and Auto-HSCT. Despite a higher risk of post-transplant progression, residual features of IFI did not affect the overall outcome of HSCT. In conclusion, a history of IFI and residual features are not contraindications to HSCT and secondary prophylaxis by broad-spectrum antifungal agents can protect patients from relapse or progression of an earlier infection.
Introduction
Invasive fungal infection (IFI) remains a major cause of death among recipients of hematopoietic SCT (HSCT). [1] [2] [3] Despite the introduction of newer drugs over the last decade, complete eradication of fungal pathogens is difficult. The possibility of post-transplant relapse of earlier IFI is extremely high and it is associated with a very dismal outcome. [4] [5] [6] Information about the feasibility of HSCT in patients with a history of IFI is limited. Few studies have focused on the secondary prophylaxis of IFI during HSCT and information about efficacy is limited. In recent years, several studies have evaluated the efficacy of secondary prophylaxis in HSCT and showed remarkable results. 4, [7] [8] [9] [10] On account of the relatively small scale of cases, further studies are needed to evaluate the feasibility of HSCT in such patients.
Earlier studies indicated that antifungal agents, such as amphotericin B, itraconazole, voriconazole and caspofungin, had high potency against fungi and were effective as secondary prophylaxis during chemotherapy and HSCT. [7] [8] [9] 11, 12 Our experience in the treatment and prophylaxis of IFI confirmed the efficacy of the above agents. In January 2001, we introduced itraconazole and amphotericin B into the secondary prophylaxis of IFI during HSCT. At the end of 2005, caspofungin and voriconazole also came into this program. To assess the feasibility of HSCT in such conditions and the efficacy of our secondary prophylaxis strategy, we retrospectively reviewed the medical records of 49 patients with a history of IFI.
Patients and methods
From January 2001 to December 2007, 537 cases of HSCT were studied in our unit, of which 49 patients had a history of IFI before HSCT, with an incidence of 9.1%. The diagnosis of IFI was documented according to the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) criteria. [13] [14] [15] The diagnosis of proven IFI (n ¼ 5) was made according to pathological evidence (n ¼ 2) or culture of blood (n ¼ 3). Probable (n ¼ 21) and possible (n ¼ 23) cases were documented by clinical, radiological or microbiological evidence and the diagnosis in all these cases was confirmed by treatment responses. The day of diagnosis of IFI was when the first positive test (radiological and/or microbiological) was performed. The characteristics of the 49 patients are illustrated in Table 1 . A total of 48 patients received conventional conditioning regimen and 1 patient with severe aplastic anemia received a reduced-intensity conditioning regimen. Standard prophylaxis for GVHD included the use of CYA or tacrolimus and short-course MTX. Corticosteroids were not used routinely; they were used for grades 2-4 acute GVHD or extensive chronic GVHD.
Antifungal treatment and prophylaxis
All patients received intensive antifungal therapy before transplantation at a median duration of 11 weeks followed by maintenance therapy, none of whom underwent surgical resection. Twenty-five patients achieved complete response (CR) before HSCT and the remaining 24 patients still had residual infections. The duration of prophylaxis can be classified into three categories: (a) from the start of conditioning to the termination of neutropenia or resolution of GVHD (n ¼ 24), (b) eradication of residual diseases (n ¼ 16) or (c) initiation of antifungal treatment because of the failure of prophylaxis (n ¼ 9). The median duration of prophylaxis was 51 days . The choice of antifungal agents was based on treatment responses and it was the continuation of preceding antifungal treatment in 31 cases. Amphotericin B (n ¼ 1) and caspofungin (n ¼ 3) were administered intravenously. Itraconazole (n ¼ 20) and voriconazole (n ¼ 23) were given intravenously and followed by oral maintenance. Two patients refused broadspectrum antifungal agents and received oral fluconazole.
The remaining patients without any earlier episodes of IFI received oral fluconazole. Adverse drug reactions to the antifungal agents were observed and recorded during the period of prophylaxis. Appearance of new lesions and an increase in established lesions of more than 20% were considered to be progressive disease (PD), while patients failing to meet either PR or PD were documented as having stable disease (SD). 16, 17 Residual disease before transplantation was defined as PR, SD or progressive disease before transplantation. Relapse was defined as the recurrence of fungal lesions in the historical foci in imaging. Breakthrough infection was defined as the emergence of fungal lesions in foci other than the historical one. Failure of prophylaxis was defined as progression of residual disease or relapse of IFI. The primary assessment end point of the secondary prophylaxis was 24 months post-transplant or death within 24 months.
Statistical considerations
For categorical variables, the w 2 statistic or Fischer's exact test was used to establish differences in their distribution, with a two-sided significance (P-value of 0.05). The incidence of the failure of prophylaxis and IFI-related death was estimated by cumulative incidence starting on the day of transplantation. Overall survival (OS) was estimated using the Kaplan-Meier method. Univariate analyses of risk factors of the failure of prophylaxis were calculated using univariate Cox regression models, whereas the log-rank test was used for OS. Post-transplant variables (GVHD, use of corticosteroids and infection with CMV) were analyzed as time-dependent covariates. Multivariate analyses were performed by Cox proportional hazards regression. 16, 18, 19 Results
Survival of the patients
After a median follow-up of 355 days (15-967), 32 of the 49 patients were alive, with an OS rate of 62.7% at 2 years after transplantation. Seventeen patients died, of whom nine died because of a relapse of the underlying disease and eight died from transplant-related causes. Three cases of IFI-related death leading to an IFI-related mortality of 6.3% at 2 years after transplantation were reported. Secondary prophylaxis of invasive fungal infection P Zhang et al
Efficacy of secondary prophylaxis
At the end of the follow-up, nine cases of failure of secondary prophylaxis were recorded, with a cumulative incidence of 18.4% at 2 years after transplantation. Seven cases experienced progression of residual infection (at days þ 10, þ 43, þ 61, þ 62, þ 62, þ 65 and þ 80, respectively) and two cases experienced relapses (at days þ 29 and þ 180), including one case of relapse at day þ 180 after the eradication of the residual disease. At day þ 22 after HSCT, one case of breakthrough invasive aspergillosis was observed in the itraconazole group. No case of recurrent or de novo infection was observed 6 months after transplantation.
Outcome of IFI in recipients of Allo-HSCT Twenty-nine cases of our patients received Allo-HSCT, of whom 13 had residual diseases before transplantation. At the end of follow-up, seven cases experienced failure of IFI prophylaxis, with a cumulative incidence of 24.1% at 2 years. Two of the seven cases died, leading to a cumulative IFI-related mortality rate of 6.9%. Meanwhile, 2 of the 20 patients in the autologous arm experienced failure of IFI prophylaxis, with one case of IFI-related mortality. No significant difference was found between the two groups.
Outcome of IFI in patients with residual diseases Twenty-four patients in our study had residual disease before transplantation, of which 15 were in PR and 9 in SD, including 4 cases with residual cavities in pulmonary CT scanning. At the end of the follow-up, seven cases experienced progression of residual infection and one case relapsed after the eradication of residual infection, leading to an accumulated incidence of 33.3% at 2 years, which was statistically different from those in CR before transplantation (4.0%, P ¼ 0.037; Figure 1 ). Two out of the eight cases died, with an accumulated IFI-related mortality rate of 8.3% at 2 years. No case of progression or relapse was recorded 6 months post-transplant and thereafter. The residual diseases were eradicated in 14 cases out of 17 survivors 6 months after transplantation, with an eradication rate of 82.4%. After 12 months of transplantation, all survivors were rid of their residual infections.
Risk factors of failure of secondary prophylaxis
Univariate analysis revealed the following risk factors of failure of secondary prophylaxis: time interval between diagnosis of IFI and transplantation (412 versus p12 weeks), residual disease before transplantation (CR versus PR/SD), post-transplant infection of CMV and use of corticosteroid for the treatment of GVHD (details in Table 2 ). Multivariate analysis confirmed residual disease before transplantation and post-transplant infection of CMV as independent risk factors. Other factors, such as duration of pre-transplant treatment or post-transplant prophylaxis, hierarchy of diagnosis (proven and probable versus possible), conditioning regimen, duration of neutropenia, GVHD, organ dysfunction, relapse of underlying disease, age and sex, had no impact on the failure of secondary prophylaxis.
Safety of prophylaxis
No severe adverse drug reactions leading to discontinuation of antifungal prophylaxis were observed in our study.
Discussion
Our results showed a relatively low rate of failure of IFI prophylaxis, which is similar to those free from a history of IFI (9.5% for proven and probable cases and 19.3% for all grades of IFI cases). Our study showed a relatively low rate of IFI-related mortality in comparison with earlier studies. [4] [5] [6] [7] [8] [9] This should be dedicated to the high active secondary prophylaxis, for most of our patients (95.9%, 47/49) received broad-spectrum antifungal agents. [7] [8] [9] The low proportion (10.2%, 5/49) of proven cases of historical IFI may explain the difference between our results and the literature, which reflects the higher severity of infection in Days after transplantation Figure 1 Cumulative incidence of failure of prophylaxis in patients with versus without residual diseases before transplantation. Secondary prophylaxis of invasive fungal infection P Zhang et al proven cases. 4, 6, 10 Most of the cases (81.6%, 40/49) received HSCT after 2004 and progress in diagnosis and therapy may be another contributor. 2 The delayed immune reconstitution after Allo-HSCT put patients at a risk of reactivation of preceding IFI. 4, 6, 7, 16 Therefore, we analyzed the outcome of IFI in the 29 patients receiving Allo-HSCT. In comparison with Auto-HSCT, there was no significant difference in the incidence of the failure of prophylaxis (24.1 versus 10% at 2 years, P ¼ 0.17), IFI-related mortality rate (6.9 versus 5% at 2 years, P ¼ 0.71) and OS rate (54.6 versus 73.6% at 2 years, P ¼ 0.18). No significant difference was found between the two groups regarding distribution of risk factors. The results indicate that Allo-HSCT is feasible for patients with a history of IFI and a favorable outcome can be achieved with powerful prophylaxis 4, 6, 16 (Figure 2 ). Earlier studies reported that residual radiological abnormalities before transplantation were a major risk factor for the failure of IFI prophylaxis, [4] [5] [6] 16 which was confirmed by our study. A total of 24 cases (49.0%) in our study had residual disease before transplantation and we assessed the outcome of the preceding IFI in this subgroup. Results showed that the cumulative incidence of disease progression and IFI-related mortality was similar to that free from a history of IFI. With regard to the survivors, most cases (82.4%) can achieve eradication of the residual diseases within 6 months after transplantation. We then analyzed the impact of residual infections on the OS. No significant difference was found between the two subgroups with and without residual infections, and the estimated OS rate at 2 years was 62.5 and 63.1%, respectively (Figure 3) . The results of this study indicate that HSCT is feasible for patients with residual infections and a similar outcome can be achieved in patients with and without residual disease through effective prophylaxis. 8, 16 Previous studies 16, 20, 21 showed that risk stratification could effectively identify those who are prone to relapse. We found the following risk factors for failure of secondary prophylaxis (Table 2) , namely residual disease before transplantation and shorter time interval from diagnosis to conditioning increased the danger of failure of secondary prophylaxis. This reflects the fact that the intensity of pre-transplant antifungal therapy exerts an impact on the outcome of post-transplant reactivation or progression. [4] [5] [6] 8, 16 However, our study failed to find a relationship between the duration of pre-transplant antifungal therapy or post-transplant prophylaxis and the outcome. This maybe was because of the wide heterogeneity of antifungal agents adopted in our study. Infection with CMV was also a risk factor of the failure of secondary prophylaxis. In the situation of Allo-HSCT, the use of corticosteroids for the treatment of GVHD would place the patients at risk. This is in line with earlier studies and reflects the importance of immune reconstitution in preventing the reactivation of IFI. 5, 6, 16, [22] [23] [24] The literature also found the following risk factors: hierarchy of diagnosis (proven and probable versus possible), conditioning regimen, duration of neutropenia, GVHD, organ dysfunction and progression of the underlying diseases. However, we failed to confirm the results of these studies.
To the best of our knowledge, this is one of the largest series of reports on the secondary prophylaxis of IFI during HSCT. There was a relatively high proportion of possible cases of IFI. This finding may exert some effect on the results. Analysis of the 26 patients with an earlier proven or probable IFI showed similar IFI-related mortality rate and incidence of failure of secondary prophylaxis (19.2% at 2 years). In this study, 42.9% (21/49) of patients had a follow-up of less than 1 year, the relatively short duration of which may have some impact on the conclusion. However, of 39 patients who survived for 6 months, no case of failure of prophylaxis was recorded 6 months after transplantation. On account of the limited size of our study population and retrospective design, only minimal information is available. Prospectively designed studies on a larger size of population with a history of proven IFI are needed to evaluate the efficacy of secondary prophylaxis strategy.
We conclude that a history of IFI and residual disease before transplantation are not absolute contraindications to HSCT. Through intensive antifungal 
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Autologous n=20 Allogeneic n=29 Figure 2 Overall survival in patients receiving autologous versus allogeneic hematopoietic stem cell transplantation.
Secondary prophylaxis of invasive fungal infection P Zhang et al therapy before transplantation and secondary prophylaxis, a similar outcome can be achieved in comparison with patients free from a history of IFI. The study showed the following risk factors of failure of secondary prophylaxis: time interval between diagnosis of IFI and transplantation, residual diseases before conditioning, infection of CMV and use of corticosteroids for the treatment of GVHD.
